News

Rural patients with cancer face crushing costs, travel hurdles, and medical debt; new ACS CAN data show care delays and highlights patient navigation as relief.

Investigators urge caution in interpreting these results, acknowledging the inherent limitations of unanchored, population-adjusted indirect trial comparisons.

The TRITON3 update supports rucaparib's role as an established option in the post-ARPI, pre-chemotherapy BRCA+ mCRPC setting.

NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and patients face next.

"Sac-TMT may be able to address a critical unmet need for certain patients with advanced endometrial cancer," said Domenica Lorusso, MD, PhD.

“These findings support the potential for a treatment holiday with enzalutamide combination [therapy] in high-risk biochemically recurrent prostate cancer," said Neal D. Shore, MD.

SunRISe-4: Genomic disease burden, TMB, and PD-L1 expression linked to pathologic overall response to neoadjuvant gemcitabine intravesical system plus cetrelimab in MIBC.

Two preoperative doses of intravesical mitomycin-C administered 1 day and 4 hours before TURBT led to a 5-year RFS rate of over 90% in NMIBC.

The pembrolizumab/BCG combo yielded clinical complete responses at 6 months in over 90% of very high-risk BCG-naive NMIBC patients.

The neoadjuvant and adjuvant FDA indications for T-DXd in HER2+ breast cancer are based on the DESTINY-Breast11 and DESTINY-Breast05 trials, respectively.

Combining durvalumab with BCG induction and maintenance therapy significantly reduced the risk of disease recurrence in BCG-naive, high-risk NMIBC.

In ARASEC, darolutamide plus ADT significantly improved survival and disease control versus ADT alone in mHSPC, complementing ARANOTE outcomes.

The FDA approved atezolizumab for the adjuvant treatment of muscle invasive bladder cancer with ctDNA molecular residual disease after cystectomy.

UGN-103 (mitomycin) for intravesical solution sustained disease control through 6 months in the UTOPIA trial in recurrent intermediate-risk LG-NMIBC.

Gedatolisib moves frontline in HR+/HER2– metastatic breast cancer, adding endocrine-sensitive patients and testing triplets vs ribociclib to boost PFS.

The FDA has granted suplexa, a non-engineered autologous cellular immunotherapy, fast track designation for patients with MSI-H colorectal cancer.

During a live event, Ronan J. Kelly, MD, MBA, and participants discussed how they use PD-1 inhibitors in patients with upper gastrointestinal cancers.

The phase 3 VOLGA trial showed perioperative durvalumab plus neoadjuvant enfortumab vedotin reduced the risk of death in muscle-invasive bladder cancer.

In an interview, Rawan Faramand, MD, discussed her research on cost-effectiveness of graft modification to prevent GVHD in hematopoietic cell transplant.

Mitomycin for intravesical solution demonstrated durable responses in 36-month follow-up data from the phase 3 ENVISION trial.

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

FDA approves an all-oral treatment for newly diagnosed acute myeloid leukemia, enhancing options for patients ineligible for intensive chemotherapy.

Sonrotoclax gains FDA approval as a promising treatment for relapsed mantle cell lymphoma, showcasing strong efficacy and safety in clinical trials.

Gene editing donor cells enabled less toxic targeted maintenance posttransplant; study was not continued for fiscal reasons.

The NEO-CYT trial began treating patients with melanoma in the perioperative setting, combining a novel agent with immune checkpoint inhibitor therapy.

Sexual activity, sexual desire, and physical function were improved by testosterone replacement therapy in men with hypogonadism post-prostatectomy.

Emiltatug ledadotin is a B7-H4–directed antibody-drug conjugate that has shown antitumor activity in adenoid cystic carcinoma and other solid tumors.

Dr Stein reviews PEACE-3 data supporting radium-223 plus enzalutamide in mCRPC and the role of bone-protecting agents in this setting.